Anthem Biosciences Ltd (ANTHEM) is currently trading at 803.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Anthem Biosciences Limited operates as an integrated life‑sciences CRDMO and specialty ingredients manufacturer, providing custom synthesis, fermentation, peptide GMP services and specialty organic molecules to global pharma, biotech and domestic industrial customers, with manufacturing units across Bommasandra and a recently commissioned Unit IV greenfield expansion near Bengaluru. Q1 FY27 consolidated revenue was Rs.418 crore with CRDMO contributing 81.5% (Rs.341 crore) and Specialty Ingredients 18.5% (Rs.78 crore); the company delivered EBITDA of Rs.176 crore (39.6% margin) and PAT of Rs.120 crore (27.1% margin), while reporting a net cash position of Rs.1,720 crore as of June 30, 2026. Anthem is mid‑ramp across its manufacturing footprint: Unit 1 is ~78% utilized on custom synthesis, Unit 2 utilization is ~50% across expanded capacities (including 140 KL fermentation), and Unit 3 (Neo Anthem) is ramping to ~30‑35% utilization, with management targeting near‑optimal utilization as Unit 4 comes online by end FY28. Management emphasises the business is inherently lumpy by quarter — roughly 60% of the year’s order book is in hand for CRDMO— and the company is prioritizing yield optimisation, cost efficiencies, technological differentiation (flow chemistry, bio‑catalysis) and disciplined capex to sustain industry‑leading margins amid volatile quarterly phasing. Near‑term commercial catalysts include regulatory clearance for semaglutide API from CDSCO, potential commercialization of several late‑phase molecules over the next 18–24 months, and the large Unit 4 capacity addition expected to materially expand manufacturing throughput and future revenue potential.

Over the past 52 weeks, Anthem Biosciences Ltd has traded between a low of ₹579.45 and a high of ₹977.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Anthem Biosciences Ltd has a market capitalization of approximately 45,545.91. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Anthem Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 79.08 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 45,545.91 Cr, Anthem Biosciences Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Anthem Biosciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Anthem Biosciences Ltd is 79.08. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations (consolidated) for the quarter ended 30 June 2026 was ₹418.22 crore.

Consolidated revenue from operations for the quarter ended 30 June 2026 was ₹418.22 crore.

Investors bought 1,71,14,604 shares, representing a 3.05% stake, at an average price of ₹744.80 per share.

Promoter Aruna Ganesh sold 1,71,14,604 shares, representing a 3.05% stake, and exited the company.